drugset / Trial / NCT05053308
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Withdrawn
Seoul National University
RandomizedParallel-groupOpen-labelTreatment
Summary
Proportional dose of sublingual fentanyl tablet (Narco®) based on daily opioid requirement versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label, noninferiority trial.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2023-05-31
- Completion
- 2023-12-31
Outcome
Outcome not reported
Stopped: “The supply of IP is disrupted”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fentanyl | Other / unclassified | 100 ug | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 200 ug | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 300 ug | Intravenous |
Indications
No indication recorded.